Synthekine

Menlo Park, CA · Founded 2018 · Privately Held (backing)

Developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments. Synthekine is based in Menlo Park, CA and was founded in 2018. Its last reported valuation was $500 million in Dec 2022. It has raised $289 million.

Last reported valuation
$500.0M
Oct 2026
Priced at
—
Total raised
$288.6M
Last round
—

Who backs Synthekine?

13 investors
InvestorType
RA Capital ManagementAsset manager
Canaan PartnersVenture capital
Emerson CollectiveOther
Deerfield ManagementVenture capital
Samsara BioCapitalVenture capital
Revelation PartnersVenture capital
Omega FundsPE / buyout
Bain Capital Life SciencesVenture capital
Rock Springs CapitalHedge fund
Janus Henderson Investors—
+ 3 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Synthekine investors

13 investors are on record for Synthekine, including RA Capital Management, Canaan Partners, Emerson Collective and Deerfield Management. By type, the record holds 5 venture capital firms, 1 hedge fund and 1 asset manager.

Free account
More of Synthekine with a free account
  • ·The complete investor list: 13 names
  • ·Watch Synthekine: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 13 firms already write checks for companies like Synthekine. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View